Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Biological differences, characterized by loss of p16 expression without gains of 1q in iEPN-PFs, as well as deregulated E2F (zeige E2F1 Antikörper) target gene transcription, are indicative of deregulated p16-CDK4/6 (zeige CDK4 Antikörper)-pRB (zeige RB1 Antikörper)-E2F (zeige E2F1 Antikörper) pathway activity
Promoter methylation was observed for the p16 gene, which was considered an early potential marker in gastric cancer.
Results show that non-promoter hypermethylation of the CDKN2A downstream locus correlates with increased ARF and INK4a mRNA expression, and that activation of these CDKN2A transcripts is associated with improved locoregional control in laryngeal squamous cell carcinomas.
E6AP (UBE3A) abundance is down-regulated in a proportion of NSCLC (non-small cell lung (zeige CDKN2B Antikörper)cancer) patients, and this correlates with low p16 (zeige ube3a Antikörper)INK4a in tumors and worse overall survival.
The current study supports a relevant role for p15 (zeige CDKN2B Antikörper), p16, and DAPK (zeige DAPK1 Antikörper) hypermethylation in the genesis of the plasma cell neoplasm. DAPK (zeige DAPK1 Antikörper) hypermethylation also might be an important step in the progression from MGUS to MM.
Transcriptome analysis revealed ARID1A (zeige ARID1A Antikörper) knockdown led to miR (zeige MLXIP Antikörper)-503 upregulation. CDKN2A was identified as a target of miR (zeige MLXIP Antikörper)-503, which contributes to cell senescence. Thus, the data suggests that ARID1A (zeige ARID1A Antikörper) deficiency promote KRAS(G12D)-driven pancreatic tumorigenesis through miR (zeige MLXIP Antikörper)-503/CDKN2A-mediated senescence.
ARF inhibits tumor growth by suppressing the ability of NRF2 (zeige GABPA Antikörper) to transcriptionally activate its target genes, including SLC7A11 (zeige SLC7A11 Antikörper), a component of the cystine/glutamate (zeige GRIN1 Antikörper) antiporter that regulates reactive oxygen species (ROS (zeige ROS1 Antikörper))-induced ferroptosis.
The expression of the nuclear and cytoplasmic forms of p16 represent two independent mechanisms, and both seemed to control proliferation in response to oncogenic stimuli, protecting the cell from malignant transformation in BRAF (zeige BRAF Antikörper)-mutated gastrointestinal stromal tumors.
Report the accuracy of ambiguous p16 immunoreactivity in predicting oncogenic HPV and high-grade squamous intraepithelial lesion outcome.
p16 hypermethylation might be a predictive factor of poor prognosis in some surgically treated cancers, particularly in NSCLC.
Cdkn2a transcripts modulate platelet production and activity in the setting of hypercholesterolemic LDLR (zeige LDLR Antikörper) knockout mice.
The expression of three tumor suppressor genes encoded in the INK4/ARF locus (p15(INK4b (zeige CDKN2B Antikörper)), p16(INK4a), and p19(ARF)) was decreased in E6AP (zeige ube3a Antikörper)(-/-) embryo fibroblasts.
Consistent with this cellular infection spectrum, we show that intra-uterine injection of ecotropic MuLE viruses expressing oncogenic HrasG12V together with knockdown of Cdkn2a induce high-grade endometrial stromal sarcomas
ARF inhibits tumor growth by suppressing the ability of NRF2 (zeige NFE2L2 Antikörper) to transcriptionally activate its target genes, including SLC7A11 (zeige SLC7A11 Antikörper), a component of the cystine/glutamate (zeige GRIN1 Antikörper) antiporter that regulates reactive oxygen species (ROS (zeige ROS1 Antikörper))-induced ferroptosis.
These findings strongly suggest that the enhanced Arf expression in oxidative stress plays compensatory protective roles against aging-related dysregulation of gene expression in adipocytes.
Increased expression of Arf in tumor stromal cells, as in tumor keratinocytes themselves, contributes to suppression of BCC carcinogenesis.
Loss of p16(INK4a) expression is associated with tumorigenesis.
TBK1 (zeige TBK1 Antikörper) regulates p16 expression and retinal ganglion cell senescence.
median survival of KPIC mice was longer than that of LSL-KrasG12D; Ink4flox/flox; Ptf1/p48 (zeige PTF1A Antikörper)-Cre mice (KIC) (89 vs 62 days) and shorter than that of KRAS (KrasG12D), TP53 (zeige TP53 Antikörper) (Trp53R172H/+) and Ptf1/p48 (zeige PTF1A Antikörper)-Cre (KPC) mice
importance of p19(Arf) for the cellular response to the low-level DNA damage incurred in culture or upon oncogene (zeige RAB1A Antikörper) expression, providing new insight into how p19(Arf) serves as a tumor suppressor.
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
, Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4)
, cell cycle inhibitor
, cell cycle regulator
, cyclin-dependent kinase 4 inhibitor A
, cyclin-dependent kinase inhibitor 2a p16Ink4a
, cyclin-dependent kinase inhibitor 2a p19Arf
, CDK4 inhibitor p16-INK4
, cell cycle negative regulator beta
, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
, multiple tumor suppressor 1
, cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4)
, cyclin-dependent kinase inhibitor 2A, isoforms 1/2
, cyclin-dependent kinase inhibitor protein
, mitochondrial smARF